ANAVEX LIFE SCIENCES CORP. - 8-K Filing

Anavex Life Sciences reports preliminary Q2 financials with $127.4M cash and plans for FDA engagement in Alzheimer's disease programs (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $AVXL

Read the full article at SEC EDGAR

More Regulatory news